A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell Carcinoma

This study is a randomized, open-label, multi-center phase II trial evaluating the efficacy and safety of the becotatug vedotin in combination with pucotenlimab regimen in patients with advanced head and neck squamous cell carcinoma who are intolerant to platinum-based therapy.

NCT Number	NCT07628855
Lead Sponsor	Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center Collaborators: Affiliated Cancer Hospital of Shantou University Medical College, The University of Hong Kong-Shenzhen Hospital
Conditions	HNPCC
Enrollment	30 participants
Start Date	2026-05-14
Primary Completion	2028-08-30 (estimated)
Study Completion	2028-08-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-05